8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Feb 23, 2026·SEC
ADC Therapeutics S.A.(ADCT)Earnings, Financials & Key Ratios
ADCT•NYSE
Price updated Jun 19, 2026
AboutADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Show more
- Revenue$81M+14.9%
- EBITDA-$107M+16.4%
- Net Income-$143M+9.6%
- EPS (Diluted)-1.12+30.9%
- Gross Margin90.57%-1.1%
- EBITDA Margin-130.91%+27.2%
- Operating Margin-133.21%+27.8%
- Net Margin-175.31%+21.3%
ADCT Key Insights
ADC Therapeutics S.A. (ADCT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Shares diluted 30.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ADCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADCT Price & Volume
ADC Therapeutics S.A. (ADCT) stock price & volume — 10-year historical chart
Loading chart...
ADCT Growth Metrics
ADC Therapeutics S.A. (ADCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-27.09%
TTM4.43%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.41%
Return on Capital
10 Years-54.71%
5 Years-43.66%
3 Years-46.99%
Last Year-43.83%
ADCT Recent Earnings
ADC Therapeutics S.A. (ADCT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.21-10.5%
$0.19
Rev
$21M+4.3%
$20M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.04+87.5%
$0.32
Rev
$23M+3.4%
$22M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.30+25.0%
$0.40
Rev
$16M-23.8%
$22M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.50-38.9%
$0.36
Rev
$19M+3.5%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.21vs $0.19-10.5% | $21Mvs $20M+4.3% |
| Q2 2026 | Mar 10, 2026 | $0.04vs $0.32+87.5% | $23Mvs $22M+3.4% |
| Q4 2025 | Nov 10, 2025 | $0.30vs $0.40+25.0% | $16Mvs $22M-23.8% |
| Q3 2025 | Aug 12, 2025 | $0.50vs $0.36-38.9% | $19Mvs $18M+3.5% |
Based on last 12 quarters of dataView full earnings history →
ADCT Peer Comparison
ADC Therapeutics S.A. (ADCT) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 AIXI | 3.31M | 6.26 | -0.04 | -82.47% | -140.37% | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 BCYC | 277.05M | 4.00 | -1.27 | 105.77% | -344.95% | -35.74% | 0.03 |
Compare ADCT vs Peers
ADC Therapeutics S.A. (ADCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADCT Income Statement
ADC Therapeutics S.A. (ADCT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.8M | 1.14M | 2.34M | 0 | 33.92M | 209.91M | 69.56M | 70.84M | 81.36M | 79.17M |
Revenue Growth % | - | -36.77% | 105.26% | -100% | - | 518.89% | -66.86% | 1.84% | 14.85% | 4.43% |
Cost of Goods Sold | 85.53M | 118.09M | 0 | 141.82M | 1.39M | 3.3M | 2.53M | 5.95M | 7.67M | 7.35M |
COGS % of Revenue | 4743.76% | 10358.42% | - | - | 4.11% | 1.57% | 3.64% | 8.4% | 9.43% | - |
Gross Profit | -83.73M▲ 0% | -116.95M▼ 39.7% | 2.34M▲ 102.0% | -141.82M▼ 6160.5% | 32.52M▲ 122.9% | 206.61M▲ 535.2% | 67.03M▼ 67.6% | 64.89M▼ 3.2% | 73.68M▲ 13.6% | 71.82M▲ 0% |
Gross Margin % | -4643.76% | -10258.42% | 100% | - | 95.89% | 98.43% | 96.36% | 91.6% | 90.57% | 90.71% |
Gross Profit Growth % | - | -39.68% | 102% | -6160.51% | 122.93% | 535.24% | -67.56% | -3.19% | 13.55% | - |
Operating Expenses | 93.47M | 127.08M | 121.74M | 77.45M | 294.24M | 329.95M | 233.01M | 195.54M | 182.06M | 190.31M |
OpEx % of Revenue | 5184.3% | 11147.46% | 5202.52% | - | 867.54% | 157.19% | 334.99% | 276.05% | 223.78% | - |
Selling, General & Admin | 7.81M | 8.6M | 14.2M | 77.23M | 136.24M | 143.49M | 105.89M | 85.91M | -6.82M | 82.03M |
SG&A % of Revenue | 432.95% | 754.56% | 606.92% | - | 401.69% | 68.36% | 152.23% | 121.28% | -8.38% | - |
Research & Development | 85.53M | 118.31M | 107.54M | 142.03M | 158M | 186.46M | 127.13M | 109.63M | 104M | 94.95M |
R&D % of Revenue | 4743.76% | 10378.33% | 4595.6% | - | 465.85% | 88.83% | 182.76% | 154.77% | 127.84% | - |
Other Operating Expenses | 137K | 166K | 0 | -141.82M | 0 | 0 | 0 | 0 | 84.87M | 1.23M |
Operating Income | -91.67M▲ 0% | -125.94M▼ 37.4% | -119.4M▲ 5.2% | -219.26M▼ 83.6% | -261.72M▼ 19.4% | -123.34M▲ 52.9% | -165.99M▼ 34.6% | -130.65M▲ 21.3% | -108.38M▲ 17.0% | -118.48M▲ 0% |
Operating Margin % | -5084.3% | -11047.46% | -5102.52% | - | -771.65% | -58.76% | -238.63% | -184.44% | -133.21% | -149.65% |
Operating Income Growth % | - | -37.39% | 5.19% | -83.64% | -19.36% | 52.87% | -34.57% | 21.29% | 17.05% | - |
EBITDA | -91.33M | -125.43M | -117.75M | -218.44M | -259.09M | -120.96M | -162.72M | -127.38M | -106.5M | -117.3M |
EBITDA Margin % | -5065.39% | -11002.46% | -5032.18% | - | -763.89% | -57.62% | -233.93% | -179.82% | -130.91% | -148.15% |
EBITDA Growth % | - | -37.34% | 6.12% | -85.51% | -18.61% | 53.32% | -34.53% | 21.72% | 16.39% | 4.07% |
D&A (Non-Cash Add-back) | 341K | 513K | 1.65M | 821K | 2.63M | 2.39M | 3.27M | 3.28M | 1.88M | 1.19M |
EBIT | -91.67M | -122.87M | -115.75M | -219.05M | -233.16M | -110.09M | -149.09M | -105.92M | -108.38M | -89.01M |
Net Interest Income | 1.03M | 2.86M | 2.1M | -4.09M | -18.27M | -34.16M | -35.78M | -37.94M | -42.82M | -43M |
Interest Income | 1.03M | 2.86M | 2.25M | 832K | 66K | 2.57M | 10.54M | 12.27M | 8.81M | 8.75M |
Interest Expense | 0 | 0 | 156K | 4.93M | 18.34M | 36.73M | 46.33M | 50.21M | 51.63M | 51.75M |
Other Income/Expense | 1.86M | 3.07M | 3.5M | -26.7M | 10.21M | -33.56M | -34.96M | -27.03M | -34.4M | -17.66M |
Pretax Income | -89.81M▲ 0% | -122.87M▼ 36.8% | -115.9M▲ 5.7% | -245.96M▼ 112.2% | -251.5M▼ 2.3% | -156.9M▲ 37.6% | -200.95M▼ 28.1% | -157.68M▲ 21.5% | -142.78M▲ 9.4% | -136.14M▲ 0% |
Pretax Margin % | -4981.36% | -10778.25% | -4953.08% | - | -741.53% | -74.75% | -288.89% | -222.6% | -175.5% | -171.95% |
Income Tax | 48K | 224K | 582K | 327K | -21.48M | 227K | 39.11M | 166K | -157K | 850K |
Effective Tax Rate % | -0.05% | -0.18% | -0.5% | -0.13% | 8.54% | -0.14% | -19.46% | -0.11% | 0.11% | -0.62% |
Net Income | -89.86M▲ 0% | -123.1M▼ 37.0% | -116.48M▲ 5.4% | -246.29M▼ 111.4% | -230.03M▲ 6.6% | -157.13M▲ 31.7% | -240.05M▼ 52.8% | -157.85M▲ 34.2% | -142.62M▲ 9.6% | -136.99M▲ 0% |
Net Margin % | -4984.03% | -10797.89% | -4977.95% | - | -678.2% | -74.86% | -345.11% | -222.83% | -175.31% | -173.02% |
Net Income Growth % | - | -36.98% | 5.37% | -111.44% | 6.6% | 31.69% | -52.78% | 34.25% | 9.64% | 8.58% |
Net Income (Continuing) | -89.86M | -123.1M | -116.48M | -246.29M | -230.03M | -157.13M | -240.05M | -157.85M | -142.62M | -136.99M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.53▲ 0% | -2.29▼ 49.7% | -1.74▲ 24.0% | -3.77▼ 116.7% | -3.00▲ 20.4% | -1.99▲ 33.7% | -2.94▼ 47.7% | -1.62▲ 44.9% | -1.12▲ 30.9% | -0.89▲ 0% |
EPS Growth % | - | -49.67% | 24.02% | -116.67% | 20.42% | 33.67% | -47.74% | 44.9% | 30.86% | 27.41% |
EPS (Basic) | -1.53 | -2.29 | -1.74 | -3.77 | -3.00 | -1.99 | -2.94 | -1.62 | -1.12 | - |
Diluted Shares Outstanding | 58.85M | 53.83M | 66.87M | 65.41M | 76.75M | 78.15M | 81.71M | 97.16M | 127.07M | 154.14M |
Basic Shares Outstanding | 58.85M | 53.83M | 66.87M | 65.41M | 76.75M | 78.15M | 81.71M | 97.16M | 127.07M | 154.14M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ADCT Balance Sheet
ADC Therapeutics S.A. (ADCT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 265.17M | 142.08M | 122.61M | 450.45M | 525.18M | 434.98M | 336.29M | 307.39M | 306.33M | 276.77M |
Cash & Short-Term Investments | 262.75M | 138.81M | 115.55M | 439.19M | 466.54M | 326.44M | 278.6M | 250.87M | 261.34M | 231.01M |
Cash Only | 262.75M | 138.81M | 115.55M | 439.19M | 466.54M | 326.44M | 278.6M | 250.87M | 261.34M | 231.01M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.93M | 372K | 2.84M | 2.69M | 32.17M | 72.97M | 25.18M | 20.32M | 29.12M | 31.05M |
Days Sales Outstanding | 390.1 | 119.11 | 442.99 | - | 346.16 | 126.89 | 132.14 | 104.68 | 130.63 | 125.93 |
Inventory | 293K | 1.2M | 0 | 0 | 11.12M | 12.07M | 16.18M | 18.39M | 4.18M | 4.78M |
Days Inventory Outstanding | 1.25 | 3.72 | - | - | 2.91K | 1.33K | 2.33K | 1.13K | 199 | 555.6 |
Other Current Assets | 0 | 0 | 0 | 410K | 0 | 199K | 5.99M | 9.45M | 11.7M | 9.94M |
Total Non-Current Assets | 6.78M | 8.48M | 15.08M | 63.24M | 92.79M | 55.88M | 18.49M | 14.59M | 16.82M | 14.73M |
Property, Plant & Equipment | 1.14M | 1.54M | 6.27M | 4.76M | 11.23M | 10.26M | 16.13M | 13.43M | 1.3M | 1.2M |
Fixed Asset Turnover | 1.58x | 0.74x | 0.37x | - | 3.02x | 20.46x | 4.31x | 5.27x | 62.73x | 58.88x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 5.4M | 6.67M | 8.43M | 10.18M | 13.58M | 14.36M | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 47.91M | 41.24M | 7.61M | 1.65M | 0 | 0 | 0 |
Other Non-Current Assets | 232K | 264K | 368K | 397K | 693K | -13.46M | 711K | 1.16M | 15.52M | 13.53M |
Total Assets | 271.95M▲ 0% | 150.56M▼ 44.6% | 137.68M▼ 8.6% | 513.69M▲ 273.1% | 617.97M▲ 20.3% | 490.86M▼ 20.6% | 354.78M▼ 27.7% | 321.98M▼ 9.2% | 323.15M▲ 0.4% | 291.5M▲ 0% |
Asset Turnover | 0.01x | 0.01x | 0.02x | - | 0.05x | 0.43x | 0.20x | 0.22x | 0.25x | 0.26x |
Asset Growth % | - | -44.64% | -8.55% | 273.1% | 20.3% | -20.57% | -27.72% | -9.25% | 0.36% | -23.18% |
Total Current Liabilities | 20.55M | 22.35M | 19.94M | 40.44M | 73.94M | 81.94M | 67.67M | 80.47M | 70.16M | 67.63M |
Accounts Payable | 7.62M | 6.75M | 3.33M | 0 | 12.08M | 12.35M | 15.57M | 18.03M | 9.18M | 5.29M |
Days Payables Outstanding | 32.51 | 20.86 | - | - | 3.17K | 1.37K | 2.25K | 1.11K | 436.39 | 399.72 |
Short-Term Debt | 0 | 0 | 0 | 4.63M | 6.58M | 12.47M | 0 | 0 | 3M | 4.63M |
Deferred Revenue (Current) | 2.32M | 1.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 834K | 23.59M | 14.11M | 4.08M | 37.94M | 47.47M | 57.99M | 57.7M |
Current Ratio | 12.91x | 6.36x | 6.15x | 11.14x | 7.10x | 5.31x | 4.97x | 3.82x | 4.37x | 4.09x |
Quick Ratio | 12.89x | 6.30x | 6.15x | 11.14x | 6.95x | 5.16x | 4.73x | 3.59x | 4.31x | 4.02x |
Cash Conversion Cycle | 358.84 | 101.96 | - | - | 95.14 | 96.15 | 219.89 | 126.65 | -106.76 | 281.82 |
Total Non-Current Liabilities | 2.24M | 1.96M | 6.58M | 137.75M | 377.95M | 329.47M | 435.36M | 444.15M | 438.82M | 440.25M |
Long-Term Debt | 0 | 0 | 0 | 107.98M | 125.1M | 109.71M | 112.73M | 113.63M | 436.01M | 416.72M |
Capital Lease Obligations | 0 | 0 | 3.9M | 2.46M | 6.99M | 6.56M | 10.18M | 8M | 1.03M | 3.42M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.08M | 1.39M | 2.68M | 3.76M | 222.32M | 189.65M | 312.45M | 2.43M | 2.81M | 23.52M |
Total Liabilities | 22.78M | 24.32M | 26.53M | 178.19M | 451.88M | 411.41M | 503.03M | 524.62M | 508.98M | 507.87M |
Total Debt | 0 | 0 | 5.03M | 115.08M | 139.7M | 129.85M | 124.38M | 123M | 439.01M | 421.36M |
Net Debt | -262.75M | -138.81M | -110.52M | -324.11M | -326.85M | -196.59M | -154.22M | -127.87M | 177.67M | 190.35M |
Debt / Equity | - | - | 0.05x | 0.34x | 0.84x | 1.63x | - | - | - | -1.95x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -3.59x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.62x |
Interest Coverage | - | - | -741.96x | -44.47x | -12.71x | -3.00x | -3.22x | -2.11x | -2.10x | -1.72x |
Total Equity | 249.17M▲ 0% | 126.24M▼ 49.3% | 111.16M▼ 12.0% | 335.5M▲ 201.8% | 166.09M▼ 50.5% | 79.45M▼ 52.2% | -148.25M▼ 286.6% | -202.64M▼ 36.7% | -185.83M▲ 8.3% | -216.38M▲ 0% |
Equity Growth % | - | -49.33% | -11.95% | 201.83% | -50.5% | -52.16% | -286.59% | -36.69% | 8.29% | -72.33% |
Book Value per Share | 4.23 | 2.35 | 1.66 | 5.13 | 2.16 | 1.02 | -1.81 | -2.09 | -1.46 | -1.40 |
Total Shareholders' Equity | 249.17M | 126.24M | 111.16M | 335.5M | 166.09M | 79.45M | -148.25M | -202.64M | -185.83M | -216.38M |
Common Stock | 397K | 401K | 4.36M | 6.31M | 6.45M | 7.31M | 7.31M | 8.43M | 11.08M | 11.23M |
Retained Earnings | -208.99M | -332.08M | -448.57M | -694.86M | -924.88M | -1.1B | -1.34B | -1.49B | -1.64B | -1.67B |
Treasury Stock | 0 | 0 | -100K | -4K | -128K | -679K | -541K | -220K | -205K | 0 |
Accumulated OCI | 5.46M | 5.66M | 5.54M | 43M | 102.83M | 1.82M | -93K | -1.42M | -517K | -802K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADCT Cash Flow Statement
ADC Therapeutics S.A. (ADCT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -74.94M | -121.36M | -121.58M | -168.73M | -233.38M | -138.31M | -118.69M | -123.83M | -141.17M | -114.55M |
Operating CF Margin % | -4156.68% | -10645.79% | -5195.77% | - | -688.09% | -65.89% | -170.63% | -174.82% | -173.52% | - |
Operating CF Growth % | - | -61.93% | -0.18% | -38.78% | -38.32% | 40.74% | 14.19% | -4.34% | -14% | 13.18% |
Net Income | -89.86M | -123.1M | -116.48M | -246.29M | -230.03M | -157.13M | -240.05M | -157.85M | -142.62M | -136.99M |
Depreciation & Amortization | 341K | 740K | 1.65M | 2.19M | 2.63M | 5.74M | 3.27M | 3.28M | 1.88M | 1.84M |
Stock-Based Compensation | 980K | 469K | 1.12M | 37.59M | 60.48M | 50.64M | 13.49M | 6.57M | 6.91M | 12.63M |
Deferred Taxes | 48K | 935K | 1.21M | 327K | -26.05M | 0 | 37.1M | 0 | 0 | 0 |
Other Non-Cash Items | 36K | -891K | -1.19M | 25.1M | -24.7M | 11.47M | 23.23M | 20.34M | 18.02M | 2.88M |
Working Capital Changes | 13.51M | 481K | -7.88M | 12.36M | -15.71M | -49.03M | 44.27M | 3.83M | -25.36M | 5.08M |
Change in Receivables | 4.82M | 895K | 192K | 0 | -30.22M | -42.75M | 47.79M | 4.77M | -8.79M | 516.86K |
Change in Inventory | 5.03M | 1.58M | -2.31M | 0 | -3.02M | -9.65M | -5.71M | -3.73M | -2.38M | -2.07M |
Change in Payables | 5.47M | -858K | -3.42M | 1.92M | 6.8M | 0 | 3.17M | 2.46M | -9.04M | -4.08M |
Cash from Investing | -3.25M | -2.51M | -2.25M | -2.83M | -6.67M | -687K | -3.22M | -867K | 395K | 653.73K |
Capital Expenditures | -3.16M | -2.47M | -2.15M | -2.81M | -3.43M | -687K | -3.22M | -867K | -264K | -45.76K |
CapEx % of Revenue | 175.04% | 216.67% | 91.79% | - | 10.11% | 0.33% | 4.62% | 1.22% | 0.32% | 0.06% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 659K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -92K | -36K | -100K | -19K | -3.24M | 0 | 0 | 0 | 0 | 699.49K |
Cash from Financing | 197.24M | -24K | 100.51M | 494.97M | 267.39M | -897K | 73.88M | 97.05M | 150.94M | 151.21M |
Debt Issued (Net) | 0 | 0 | -1M | 61.75M | 48.61M | -2.71M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 197.24M | 0 | -141K | 433.16M | 0 | -1.31M | 0 | 60.51M | 152.46M | 58.98M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -24K | -141K | 0 | 0 | -1.31M | 0 | 0 | 0 | -270K |
Other Financing | 0 | -24K | 101.66M | 54K | 218.78M | 3.13M | 73.88M | 36.55M | -1.51M | 92.24M |
Net Change in Cash | 119.08M▲ 0% | -123.94M▼ 204.1% | -23.26M▲ 81.2% | 323.64M▲ 1491.7% | 27.35M▼ 91.5% | -140.1M▼ 612.3% | -47.84M▲ 65.9% | -27.73M▲ 42.0% | 10.47M▲ 137.8% | 36.31M▲ 0% |
Free Cash Flow | -78.1M▲ 0% | -123.83M▼ 58.6% | -123.73M▲ 0.1% | -171.54M▼ 38.6% | -239.75M▼ 39.8% | -139M▲ 42.0% | -121.9M▲ 12.3% | -124.7M▼ 2.3% | -141.44M▼ 13.4% | -114.59M▲ 0% |
FCF Margin % | -4331.72% | -10862.46% | -5287.56% | - | -706.88% | -66.22% | -175.25% | -176.04% | -173.85% | -144.73% |
FCF Growth % | - | -58.55% | 0.08% | -38.64% | -39.77% | 42.02% | 12.3% | -2.3% | -13.42% | 16.16% |
FCF per Share | -1.33 | -2.30 | -1.85 | -2.62 | -3.12 | -1.78 | -1.49 | -1.28 | -1.11 | -0.74 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.99x | 1.04x | 0.69x | 1.01x | 0.88x | 0.49x | 0.78x | 0.99x | 0.84x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 10.18M | 15.39M | 15.7M | 0 | 7.29M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADCT Key Ratios
ADC Therapeutics S.A. (ADCT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -65.58% | -98.13% | -110.28% | -91.72% | -127.99% | - | - | - | 65.27% |
Return on Invested Capital (ROIC) | - | -14080.07% | -2734.63% | - | - | - | - | - | 48.29% |
Gross Margin | -10258.42% | 100% | - | 95.89% | 98.43% | 96.36% | 91.6% | 90.57% | 90.71% |
Net Margin | -10797.89% | -4977.95% | - | -678.2% | -74.86% | -345.11% | -222.83% | -175.31% | -173.02% |
Debt / Equity | - | 0.05x | 0.34x | 0.84x | 1.63x | - | - | - | -1.95x |
Interest Coverage | - | -741.96x | -44.47x | -12.71x | -3.00x | -3.22x | -2.11x | -2.10x | -1.72x |
FCF Conversion | 0.99x | 1.04x | 0.69x | 1.01x | 0.88x | 0.49x | 0.78x | 0.99x | 0.84x |
Revenue Growth | -36.77% | 105.26% | -100% | - | 518.89% | -66.86% | 1.84% | 14.85% | 4.43% |
Related:ADCT Dividend History·ADCT Revenue History·ADCT Price History·ADCT P/E History·ADCT Financial Ratios·ADCT Institutional Holders
ADCT SEC Filings & Documents
ADC Therapeutics S.A. (ADCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ADCT Frequently Asked Questions
ADC Therapeutics S.A. (ADCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ADC Therapeutics S.A. (ADCT) reported $79.2M in revenue for fiscal year 2025. This represents a 4291% increase from $1.8M in 2017.
ADC Therapeutics S.A. (ADCT) grew revenue by 14.9% over the past year. This is steady growth.
ADC Therapeutics S.A. (ADCT) reported a net loss of $137.0M for fiscal year 2025.
Dividend & Returns
ADC Therapeutics S.A. (ADCT) had negative free cash flow of $114.6M in fiscal year 2025, likely due to heavy capital investments.